Morgan Stanley Maintains Equal-Weight on ACADIA Pharmaceuticals, Raises Price Target to $30
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Jeffrey Hung has maintained an Equal-Weight rating on ACADIA Pharmaceuticals (NASDAQ:ACAD) and raised the price target from $21 to $30.
July 14, 2023 | 2:48 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Morgan Stanley has maintained an Equal-Weight rating on ACADIA Pharmaceuticals and raised the price target from $21 to $30.
The raised price target by Morgan Stanley indicates a positive outlook for ACADIA Pharmaceuticals. This could potentially lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100